AbbVie and Simcere Zaiming Collaborate on Novel Trispecific Antibody for Multiple Myeloma Treatment

Partnership:
AbbVie has partnered with Simcere Zaiming, a subsidiary of Simcere Pharmaceutical, to develop SIM0500, a trispecific antibody candidate for treating relapsed or refractory multiple myeloma13.

SIM0500 Details:
SIM0500 targets GPRC5D, BCMA, and CD3, leveraging a low-affinity/high-activation CD3 engaging arm and binding sites for two tumor antigens. It is currently in Phase 1 clinical trials in the U.S. and China13.

Financial Terms:
The deal includes an undisclosed upfront payment, with Simcere eligible for up to $1.05 billion in milestone payments and tiered royalties on sales outside Greater China13.

AbbVie’s Commitment:
This partnership aligns with AbbVie’s commitment to advancing innovative treatments for complex cancers like multiple myeloma through R&D efforts and collaborations13.

T-Cell Engager Platform:
SIM0500 uses Simcere’s proprietary T-cell engager platform, which has shown strong T-cell-mediated cytotoxicity against multiple myeloma cells in preclinical studies13.

Sources:

1. https://www.biopharmatrend.com/post/1110-abbvie-partners-with-simcere-on-t-cell-engager-for-multiple-myeloma-in-1b-deal/

3. https://www.prnewswire.com/news-releases/abbvie-and-simcere-zaiming-announce-partnership-to-develop-a-novel-trispecific-antibody-candidate-in-multiple-myeloma-302348650.html